ESC 365 - Concluding remarks - PSCK9 inhibition: a new horizon in LDL-C management.

Back

ESC Premium Access

Concluding remarks - PSCK9 inhibition: a new horizon in LDL-C management.

Session: PSCK9 inhibition: a new horizon in LDL-C management

Topic: Lipids

Speaker: Professor A. Catapano (Milan, IT)

About the speaker

Professor Alberico Catapano

IRCCS - MultiMedica, Milan (Italy)

46 presentations

3 followers

6 more presentations in this session

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Speaker: Professor C. Cannon (Boston, US)

Access

LDL-C exposure and atherosclerosis progression.

Speaker: Professor A. Catapano (Milan, IT)

Access

PCSK9 inhibition: the data today and tomorrow.

Speaker: Professor S. Nicholls (Melbourne, AU)

Access

Learnings and clinical insights from SPIRE.

Speaker: Doctor P. Ridker (Boston, US)

Access

Guidelines: commonalities and discrepancies.

Speaker: Doctor J. Robinson (Iowa, US)

Access

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

Speakers: Professor A. Catapano, Professor C. Cannon, Professor A. Catapano, Professor S. Nicholls, Doctor P. Ridker...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Concluding remarks - PSCK9 inhibition: a new horizon in LDL-C management.

About the speaker

Professor Alberico Catapano

6 more presentations in this session

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

LDL-C exposure and atherosclerosis progression.

PCSK9 inhibition: the data today and tomorrow.

Learnings and clinical insights from SPIRE.

Guidelines: commonalities and discrepancies.

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

About the event

ESC Congress 2017

ESC 365 is supported by